• CDX antibody offers a novel approach to treat acute myeloid leukaemia and condition patients for bone marrow transplantation • Partnership discussion progressing, could demonstrate significant upside • Encouraging preclinical datasets, with proof of concept demonstrated in vivo • Pre-IND FDA meeting for CDX Ab platform expected within 12 months • Bone marrow transplantation represents a large market • ‘Targeted Conditioning’ approach for bone marrow
29 Aug 2019
Targeting blood malignancies
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Targeting blood malignancies
HemoGenyx Pharmaceuticals Plc (HEMO:LON) | 1.7 0 (-1.3%) | Mkt Cap: 23.3m
- Published:
29 Aug 2019 -
Author:
Vadim Alexandre | Liam Gascoigne-Cohen -
Pages:
29
• CDX antibody offers a novel approach to treat acute myeloid leukaemia and condition patients for bone marrow transplantation • Partnership discussion progressing, could demonstrate significant upside • Encouraging preclinical datasets, with proof of concept demonstrated in vivo • Pre-IND FDA meeting for CDX Ab platform expected within 12 months • Bone marrow transplantation represents a large market • ‘Targeted Conditioning’ approach for bone marrow